NeoGenomics Q3 2026: Strong Revenue Growth, Raised Guidance and CEO Transition Plan
NeoGenomics 2026 Q3 results show 12.6% revenue growth, $30.4M operating profit, and a raised $807‑$809M revenue outlook—boosting its precision oncology lab services.
3 minutes to read